Would you recommend EGFR directed therapy in right sided metastatic colon cancer who are KRAS / NRAS wildtype?
Does "negative hyperselection" done in the PARADIGM study adequately identify patients where EGFR inhibitors can be used in initial treatment?
Answer from: Medical Oncologist at Academic Institution
We have known for some time that patients whose tumors harbor KRAS or NRAS mutations do not benefit from the use of anti-EGFR antibodies (cetuximab and panitumumab). Recent analyses of the Alliance/SWOG 80405 trial and the European FIRE-3 trial (both for 1st line metastatic KRAS wild-type CRC treate...
Sign in or Register to read more